DrugCard is a pharmacovigilance platform that automates literature screening, regulatory intelligence, and adverse-event monitoring for drug-safety teams. Brothers Artem and Dmytro Horilyk founded the company in 2019 in Tallinn, Estonia, after Artem's work as a pharmacovigilance specialist exposed how much of the screening process was still done by hand.
The platform's AI reads and screens medical literature across more than 100 languages and 1,500-plus local journals, a specific focus on local-language sources that most competing tools skip, and surfaces adverse-event signals for review instead of requiring specialists to read every article manually. Regulatory intelligence and safety-database features round out the platform for teams that need to document compliance, not only flag risks.
DrugCard fits pharmacovigilance and drug-safety teams at pharmaceutical companies operating across multiple countries and languages. The company reports operations in 121-plus countries and more than a million articles processed; it includes a free two-week trial, with full pricing quoted directly since the company does not publish rates.
